Andrx’ Fortamet picks up exclusivity
Andrx' Fortamet (metformin extended-release) awarded three years of Waxman/Hatch marketing exclusivity, company says June 7. Fortamet launched in May; FDA approved Andrx' 505(b)(2) application for the antidiabetic agent April 27 (1"The Pink Sheet" May 3, 2004, p. 16)...
You may also be interested in...
Andrx will highlight the dosing convenience for Fortamet (metformin extended-release) in an effort to distinguish the antidiabetic agent from Glucophage XR and its generics
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.
Entries are now open for the Global Generics & Biosimilars Awards 2021, which will take place in Milan, Italy on 10 November.